Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review

References

• Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2018. Blood Cancer J. 2018;8:93. doi:10.1038/s41408-018-0131-230283014
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390. doi:10.1182/blood-2016-01-64356926980727
   PubMed Web of Science ®Google Scholar
• Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333:1052–1057. doi:10.1056/NEJM1995101933316067675049
   PubMed Web of Science ®Google Scholar
• Rai KR, Jain P. Chronic lymphocytic leukemia (CLL) - then and now. Am J Hematol. 2016;91:330–340. doi:10.1002/ajh.2428226690614
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92:946–965. doi:10.1002/ajh.2482628782884
   PubMed Web of Science ®Google Scholar
• Filip AA, Grenda A, Popek S, et al. Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle. Ann Hematol. 2017;96(1):33–50. doi:10.1007/s00277-016-2840-627730344
   PubMed Web of Science ®Google Scholar
• Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood. 1999;94:448–454. doi:10.1182/blood.V94.2.44810397712
   PubMed Web of Science ®Google Scholar
• Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Prim. 2017;3:17008. doi:10.1038/nrdp.2017.828179635
   PubMed Web of Science ®Google Scholar
• Pan JW, Cook LS, Schwartz SM, Weis NS. Incidence of leukemia in Asian migrants to the United States and their descendants. Cancer Causes Control. 2002;13:791–795. doi:10.1023/A:102060832896912462543
   PubMed Web of Science ®Google Scholar
• Nabhan C, Aschebrook-Kilfoy B, Chiu BC, et al. The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive surveillance, epidemiology, and end results analysis in the modern era. Leuk Lymphoma. 2014;55:2778–2784. doi:10.3109/10428194.2014.89875824588735
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Robak T, Montserrat E, et al.; ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v50–54. doi:10.1093/annonc/mdv303
   Web of Science ®Google Scholar
• Eichhorst B, Hallek M. Prognostication of chronic lymphocytic Leukemia in the era of new agents. Hematology Am Soc Hematol Educ Program. 2016;2016:149–155. doi:10.1182/asheducation-2016.1.14927913474
   PubMed Web of Science ®Google Scholar
• Gaidano G, Rossi D. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. Hematology Am Soc Hematol Educ Program. 2017;2017:329–337. doi:10.1182/asheducation-2017.1.32929222275
   PubMed Web of Science ®Google Scholar
• Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526:525–530. doi:10.1038/nature1539526466571
   PubMed Web of Science ®Google Scholar
• Puente XS, Beà S, Valdés-Mas R, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526:519–524. doi:10.1038/nature1466626200345
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–1916. doi:10.1056/NEJM20001228343260211136261
   PubMed Web of Science ®Google Scholar
• Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17:28–40. doi:10.1016/j.ccr.2009.11.01920060366
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322. doi:10.1056/NEJMoa151325726639348
   PubMed Web of Science ®Google Scholar
• Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121:1403–1412. doi:10.1182/blood-2012-09-45826523243274
   PubMed Web of Science ®Google Scholar
• Guarini A, Marinelli M, Tavolaro S, et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica. 2012;97:47–55. doi:10.3324/haematol.2011.04927021993670
   PubMed Web of Science ®Google Scholar
• Rossi D, Gaidano G. The clinical implications of gene mutations in chronic lymphocytic leukaemia. Br J Cancer. 2016;114:849–854. doi:10.1038/bjc.2016.7827031852
   PubMed Web of Science ®Google Scholar
• Seiffert M, Dietrich S, Jethwa A, Glimm H, Lichter P, Zenz T. Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:1023–1031. doi:10.3109/10428194.2011.63163822023519
   PubMed Web of Science ®Google Scholar
• Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2008;142:202–215. doi:10.1111/j.1365-2141.2008.07166.x18492108
   PubMed Web of Science ®Google Scholar
• Autore F, Strati P, Laurenti L, Ferrajoli A. Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review. Haematologica. 2018;106:931–938. doi:10.3324/haematol.2017.186684
   Web of Science ®Google Scholar
• Campo E, Cymbalista F, Ghia P, et al. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica. 2018;103:1956–1968. doi:10.3324/haematol.2018.18758330442727
   PubMed Web of Science ®Google Scholar
• Condoluci A, Terzi Di Bergamo L, Langerbeins P. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020;135(21):1859–1869. doi:10.1182/blood.201900345332267500
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–1854. doi:10.1182/blood.V94.6.184810477713
   PubMed Web of Science ®Google Scholar
• Brachtl G, Piñón Hofbauer J, Greil R, Hartmann TN. The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia. Ann Hematol. 2014;93:361–374. doi:10.1007/s00277-013-1967-y24288111
   PubMed Web of Science ®Google Scholar
• D’Arena G, Tarnani M, Rumi C, et al. Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. Am J Hematol. 2007;82:787–791. doi:10.1002/ajh.2093617534928
   PubMed Web of Science ®Google Scholar
• Malavasi F, Deaglio S, Funaro A, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 2008;88:841–886. doi:10.1152/physrev.00035.200718626062
   PubMed Web of Science ®Google Scholar
• Kumagai M, Coustan-Smith E, Murray DJ, et al. Ligation of CD38 suppresses human B lymphopoiesis. J Exp Med. 1995;181:1101–1110. doi:10.1084/jem.181.3.11017869031
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–1847. doi:10.1182/blood.V94.6.184010477712
   PubMed Web of Science ®Google Scholar
• Dürig J, Naschar M, Schmücker U, et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia. 2002;16:30–35. doi:10.1038/sj.leu.240233911840260
   PubMed Web of Science ®Google Scholar
• Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410–1416. doi:10.1182/blood.V100.4.1410.h81602001410_1410_141612149225
   PubMed Web of Science ®Google Scholar
• Rose DM, Han J, Ginsberg MH. Alpha4 integrins and the immune response. Immunol Rev. 2002;186:118–124. doi:10.1034/j.1600-065X.2002.18611.x12234367
   PubMed Web of Science ®Google Scholar
• Rettig MP, Ansstas G, DiPersio JF. Mobilization ofhematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia. 2012;26:34–53.21886173
   PubMed Web of Science ®Google Scholar
• Gattei V, Bulian P, Del Principe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood. 2008;111:865–873. doi:10.1182/blood-2007-05-09248617959854
   PubMed Web of Science ®Google Scholar
• Scielzo C, Camporeale A, Geuna M, et al. ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage. Leukemia. 2006;20:689–695. doi:10.1038/sj.leu.240413816482211
   PubMed Web of Science ®Google Scholar
• Wang YH, Fan L, Xu W, Li JY. Detection methods of ZAP-70 in chronic lymphocytic leukemia. Clin Exp Med. 2012;12:69–77. doi:10.1007/s10238-011-0148-321691729
   PubMed Web of Science ®Google Scholar
• Shanafelt TD. Predicting clinical outcome in CLL: how and why. Hematology Am Soc Hematol Educ Program. 2009;421–429. doi:10.1182/asheducation-2009.1.42120008228
   PubMedGoogle Scholar
• Boudny M, Zemanova J, Khirsariya P, et al. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. Haematologica. 2019;104:2443–2455. doi:10.3324/haematol.2018.20343030975914
   PubMed Web of Science ®Google Scholar
• Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2012;119:521–529. doi:10.1182/blood-2011-09-37996622077063
   PubMed Web of Science ®Google Scholar
• Cortese D, Sutton LA, Cahill N, et al. On the way towards a ‘CLL prognostic index’: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort. Leukemia. 2014;28:710–713. doi:10.1038/leu.2013.33324217197
   PubMed Web of Science ®Google Scholar
• Tausch E, Beck P, Schlenk RF, et al. NOTCH1 mutation and treatment outcome in CLL patients treated with chlorambucil (Chl) or ofatumumab-Chl (O-Chl): results from the Phase III study complement 1 (OMB110911). Blood. 2013;122:527.
   Web of Science ®Google Scholar
• Pozzo F, Bittolo T, Arruga F, et al. NOTCH1 mutations. associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation- driven epigenetic dysregulation. Leukemi. 2015;30:182–189. doi:10.1038/leu.2015.182
   PubMed Web of Science ®Google Scholar
• Amin NA, Malek SN. Gene mutations in chronic lymphocytic leukemia. Semin Oncol. 2016;43:215–221. doi:10.1053/j.seminoncol.2016.02.00227040699
   PubMed Web of Science ®Google Scholar
• Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=TP53. Accessed 1219, 2020.
   Google Scholar
• Kastenhuber E, Lowe S. Putting p53 in context. Cell. 2017;170:1062–1078. doi:10.1016/j.cell.2017.08.02828886379
   PubMed Web of Science ®Google Scholar
• Minervini CF, Cumbo C, Orsini P, et al. TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing. Diagn Pathol. 2016;11:1–9. doi:10.1186/s13000-016-0550-y26746436
   PubMed Web of Science ®Google Scholar
• Guièze R, Pages M, Véronèse L, et al. Telomere status in chronic lymphocytic leukemia with TP53 disruption. Oncotarget. 2016;7:56976–56985. doi:10.18632/oncotarget.1092727486974
   PubMed Web of Science ®Google Scholar
• White E. Autophagy and p53. Cold Spring Harb Perspect Med. 2016;6(4):a026120. doi:10.1101/cshperspect.a02612027037419
   PubMed Web of Science ®Google Scholar
• Dai CQ, Luo TT, Luo SC, et al. p53 and mitochondrial dysfunction: novel insight of neurodegenerative diseases. J Bioenerg Biomembr. 2016;48(4):337–347. doi:10.1007/s10863-016-9669-527422544
   PubMed Web of Science ®Google Scholar
• Leroy B, Ballinger ML, Baran-Marszak F, et al. Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice. Cancer Res. 2017;77:1250–1260. doi:10.1158/0008-5472.CAN-16-217928254861
   PubMed Web of Science ®Google Scholar
• Edelmann J, Gribben JG. Managing patients with TP53-deficient chronic lymphocytic leukemia. J Oncol Pract. 2017;13:371–377. doi:10.1200/JOP.2017.02329128605616
   PubMed Web of Science ®Google Scholar
• Zenz T, Vollmer D, Trbusek M, et al.; European Research Initiative on CLL (ERIC). TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia. 2010;24:2072–2079. doi:10.1038/leu.2010.20820861914
   PubMed Web of Science ®Google Scholar
• Shlush LI, Hershkovitz D. Clonal evolution models of tumor heterogeneity. Am Soc Clin Oncol Educ Book. 2015;e662–5. doi:10.14694/EdBook_AM.2015.35.e66225993239
   PubMedGoogle Scholar
• Rossi D, Khiabanian H, Spina V, et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood. 2014;123(14):2139–2147. doi:10.1182/blood-2013-11-53972624501221
   PubMed Web of Science ®Google Scholar
• Pospisilova S, Gonzalez D, Malcikova J, et al.; European Research Initiative on CLL (ERIC). TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia. 2012;26:1458–1461. doi:10.1038/leu.2012.2522297721
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al.; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456. doi:10.1182/blood-2007-06-09390618216293
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123:3247–3255. doi:10.1182/blood-2014-01-54615024652989
   PubMed Web of Science ®Google Scholar
• Parikh SA, Strati P, Tsang M, West CP, Shanafelt TD. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. Blood. 2016;127:1752–1761. doi:10.1182/blood-2015-10-62086426841802
   PubMed Web of Science ®Google Scholar
• Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol. 1928;4:285–292.19969796
   PubMedGoogle Scholar
• Wang Y, Tschautscher MA, Rabe KG, et al. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 2020;105:765–773. doi:10.3324/haematol.2019.22412131197071
   PubMed Web of Science ®Google Scholar
• Fabbri G, Khiabanian H, Holmes AB, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med. 2013;210:2273–2288. doi:10.1084/jem.2013144824127483
   PubMed Web of Science ®Google Scholar
• Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018;131:2761–2772. doi:10.1182/blood-2018-01-79137629692342
   PubMed Web of Science ®Google Scholar
• Rossi D, Gaidano G. Richter syndrome: pathogenesis and management. Semin Oncol. 2016;43:311–319. doi:10.1053/j.seminoncol.2016.02.01227040710
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25:5616–5623. doi:10.1200/JCO.2007.12.909817984186
   PubMed Web of Science ®Google Scholar
• Rafei H, Kharfan-Dabaja MA. Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies. Hematol Oncol Stem Cell Ther. 2018;11:1–12. doi:10.1016/j.hemonc.2017.04.00228549767
   PubMedGoogle Scholar
• Yosifov D, Wolf C, Stilgenbauer S, Mertens D. From biology to therapy: the CLL success story. HemaSphere. 2019;3:e175. doi:10.1097/HS9.000000000000017531723816
   PubMed Web of Science ®Google Scholar
• Isaac K, Mato AR. Acalabrutinib and its therapeutic potential in the treatment of chronic lymphocytic leukemia: a short review on emerging data. Cancer Manag Res. 2020;12:2079–2085. doi:10.2147/CMAR.S21957032256115
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42. doi:10.1056/NEJMoa121563723782158
   PubMed Web of Science ®Google Scholar
• O’Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131:1910–1919. doi:10.1182/blood-2017-10-81004429437592
   PubMed Web of Science ®Google Scholar
• Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16:169–176. doi:10.1016/S1470-2045(14)71182-925555420
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al.; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–1174. doi:10.1016/S0140-6736(10)61381-520888994
   PubMed Web of Science ®Google Scholar
• Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874–879. doi:10.3324/haematol.2017.18290729419429
   PubMed Web of Science ®Google Scholar
• Burger JA, Li KW, Keating MJ, et al. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight. 2017;2(2):e89904. doi:10.1172/jci.insight.8990428138560
   PubMed Web of Science ®Google Scholar
• Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182–1189. doi:10.1182/blood-2011-10-38641722180443
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007. doi:10.1056/NEJMoa131522624450857
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood. 2015;126:2686–2694. doi:10.1182/blood-2015-03-63094726472751
   PubMed Web of Science ®Google Scholar
• Jones JA, Robak T, Brown JR, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017;4:e114–e126. doi:10.1016/S2352-3026(17)30019-428257752
   PubMed Web of Science ®Google Scholar
• Coutré SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56:2779–2786. doi:10.3109/10428194.2015.102277025726955
   PubMed Web of Science ®Google Scholar
• Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278–1291. doi:10.1016/S0140-6736(20)30262-232305093
   PubMed Web of Science ®Google Scholar
• Ghia P, Pluta A, Wach M, et al. ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38:2849–2861. doi:10.1200/JCO.19.0335532459600
   PubMed Web of Science ®Google Scholar
• Aitken MJL, Lee HJ, Post SM. Emerging treatment options for patients with p53-pathway-deficient CLL. Ther Adv Hematol. 2019;10:2040620719891356. doi:10.1177/204062071989135631839919
   PubMed Web of Science ®Google Scholar
• Syed YY. Zanubrutinib: first approval. Drugs. 2020;80:91–97. doi:10.1007/s40265-019-01252-431933167
   PubMed Web of Science ®Google Scholar
• Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134:851–859. doi:10.1182/blood.201900116031340982
   PubMed Web of Science ®Google Scholar
• Flinn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132:2446–2455. doi:10.1182/blood-2018-05-85046130287523
   PubMed Web of Science ®Google Scholar
• Barr PM, Saylors GB, Spurgeon SE, et al. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 2016;127:2411–2415. doi:10.1182/blood-2015-12-68351626968534
   PubMed Web of Science ®Google Scholar
• Available from: https://clinicaltrials.gov/ct2/show/NCT03010358. Accessed 1219, 2020.
   Google Scholar
• Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 1993;82:1820–1828. doi:10.1182/blood.V82.6.1820.18208104532
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768–778. doi:10.1016/S1470-2045(16)30019-527178240
   PubMed Web of Science ®Google Scholar
• Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19:65–75. doi:10.1016/S1470-2045(17)30909-929246803
   PubMed Web of Science ®Google Scholar
• Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-venetoclax-cll-and-sll. Accessed 1219, 2020.
   Google Scholar
• Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225–2236. doi:10.1056/NEJMoa181528131166681
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107–1120. doi:10.1056/NEJMoa171397629562156
   PubMed Web of Science ®Google Scholar
• Kater AP, Wu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO Phase III study. J Clin Oncol. 2020;28:JCO2000948.
   Google Scholar
• Roberts AW, Ma S, Kipps TJ, et al. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019;134(2):111–122. doi:10.1182/blood.201888255531023700
   PubMed Web of Science ®Google Scholar
• Levin MD, Kater A, Mattsson M, et al. Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised Phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations. BMJ Open. 2020;10(10):e039168. doi:10.1136/bmjopen-2020-039168
   PubMed Web of Science ®Google Scholar
• Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18:230–240. doi:10.1016/S1470-2045(17)30012-828089635
   PubMed Web of Science ®Google Scholar
• Zou Y, Xu W, Li J. Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia. J Hematol Oncol. 2018;11:130. doi:10.1186/s13045-018-0676-330458878
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hay KA, Hanafi LA, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of Ibrutinib. J Clin Oncol. 2017;35:3010–3020. doi:10.1200/JCO.2017.72.851928715249
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–195. doi:10.1182/blood-2014-05-55272924876563
   PubMed Web of Science ®Google Scholar
• Sedlarikova L, Petrackova A, Papajik T, et al. Resistance-associated mutations in chronic lymphocytic leukemia patients treated with novel agents. Front Oncol. 2020;10:894. doi:10.3389/fonc.2020.0089432670873
   PubMed Web of Science ®Google Scholar
• Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286–2294. doi:10.1056/NEJMoa140002924869598
   PubMed Web of Science ®Google Scholar
• Gángó A, Alpár D, Galik B, et al. Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. Int J Cancer. 2020;146:85–93. doi:10.1002/ijc.3250231180577
   PubMed Web of Science ®Google Scholar
• Bartkova J, Horejsí Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–870. doi:10.1038/nature0348215829956
   PubMed Web of Science ®Google Scholar
• Carrà G, Panuzzo C, Torti D, et al. Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones. Oncotarget. 2017;8:35508–35522. doi:10.18632/oncotarget.1634828418900
   PubMedGoogle Scholar
• Liu J, Chen G, Pelicano H, et al. Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROS-mediated mechanism. Oncotarget. 2016;7:71378–71389. doi:10.18632/oncotarget.1211027655686
   PubMedGoogle Scholar
• Ranjan A, Ramachandran S, Gupta N, et al. Role of phytochemicals in cancer prevention. Int J Mol Sci. 2019;20:4981. doi:10.3390/ijms20204981
   PubMed Web of Science ®Google Scholar
• Ciardullo C, Aptullahoglu E, Woodhouse L, et al. Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells. Haematologica. 2019;104(12):2429–2442. doi:10.3324/haematol.2018.20663131004033
   PubMed Web of Science ®Google Scholar